Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
endostatin:angiostatin fusion protein
- Development stage
- Preclinical
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intratumoral, Intravenous, Subcutaneous, Intramuscular, Intraperitoneal, Oral, Rectal, Vaginal, Parenteral
01
Overview
**Endostatin:angiostatin fusion protein** is an experimental recombinant antiangiogenic fusion protein consisting of endostatin linked to angiostatin. In the cited nonviral gene-transfer study, the ES:AS transgene was inserted into an EBNA1-OriP plasmid, electroporated into B16F10 melanoma and RENCA renal carcinoma cells, and expressed as a secreted protein. Expression delayed and reduced primary tumor formation in murine melanoma and renal carcinoma models, reduced B16F10 lung metastases, and showed greater antitumor activity than angiostatin alone. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/15031722/))
- Other names
- endostatin-angiostatin fusion proteinendostatin/angiostatin fusion proteinendostatin:angiostatin fusion proteinES:AS
02
Targets
CAV1 (Caveolin-1)Cell surface ATP synthaseGPC (Lassa virus glycoprotein complex)HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))ITGA5:ITGB1 (Integrin α5β1)αVβ3 (Integrin αVβ3)αVβ5 (Integrin αVβ5)MMP13 (Matrix metalloproteinase-13)MMP2 (Matrix metalloproteinase-2)MMP9 (Matrix metalloproteinase-9)ATP SynthaseNCL (Nucleolin)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on endostatin:angiostatin fusion protein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on endostatin:angiostatin fusion protein.